Search results
Showing 951 to 1000 of 2048 results for work
Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults.
Evidence-based recommendations on anakinra (Kineret) for treating adult-onset Still’s disease and systemic juvenile idiopathic arthritis in people 8 months and older.
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)
Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive, locally recurrent or metastatic (secondary) breast cancer that has not been treated with chemotherapy or targeted HER-2 therapy before, in adults.
Evidence standards framework for digital health technologies (ECD7)
This document describes an evidence standards framework (ESF) for digital health technologies (DHTs). It was developed by NICE between June 2018 and February 2019 in collaboration with NHS England, Public Health England and MedCity. The work was commissioned by NHS England
Discontinued Reference number: GID-TA10525
Discontinued Reference number: GID-TA10937
Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer in adults.
View recommendations for TA1109Show all sections
Discontinued Reference number: GID-TA10929
Parsaclisib for treating relapsed or refractory marginal zone lymphoma [ID3976]
Discontinued Reference number: GID-TA10863
Discontinued Reference number: GID-TA10208
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]
Discontinued Reference number: GID-HST10004
Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer [ID3752]
Discontinued Reference number: GID-TA10617
Discontinued Reference number: GID-TA10144
Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]
Discontinued Reference number: GID-TA10750
Discontinued Reference number: GID-TA10707
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]
Discontinued Reference number: GID-TA10728
Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]
Discontinued Reference number: GID-TA10848
Nivolumab for neoadjuvant and adjuvant treatment of localised renal cell carcinoma [ID4047]
Discontinued Reference number: GID-TA10927
Discontinued Reference number: GID-TA10880
Percutaneous insertion of a cerebral protection device during TAVI for preventing stroke
In development Reference number: GID-IPG10439 Expected publication date: 11 February 2027
Venetoclax with ibrutinib and obinutuzumab for untreated chronic lymphocytic leukaemia ID1270
Discontinued Reference number: GID-TA10211
Discontinued Reference number: GID-TA11258
Capecitabine for the treatment of advanced pancreatic cancer [ID127]
Discontinued Reference number: GID-TA11239
Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma [ID3940]
Discontinued Reference number: GID-TA10830
NICE has developed a medtech innovation briefing (MIB) on Optowire for measuring fractional flow reserve .
Discontinued Reference number: GID-TA10768
Cendakimab for treating eosinophilic oesophagitis in people 12 years TS ID 12088
Discontinued Reference number: GID-TA11702
Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]
Discontinued Reference number: GID-TA10851
Pazopanib for adjuvant treatment of locally advanced renal cell carcinoma [ID1091]
Discontinued Reference number: GID-TA11240
Masitinib for treating relapsed or refractory peripheral T-cell non-Hodgkin lymphoma [ID1125]
Discontinued Reference number: GID-TA11173
Discontinued Reference number: GID-TA10474
Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]
Discontinued Reference number: GID-TA11261
Discontinued Reference number: GID-TA10875
Discontinued Reference number: GID-TA10149
Terevalefim for treating delayed graft function after kidney transplant [ID1490]
Discontinued Reference number: GID-TA11098
Nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer [ID1228]
Discontinued Reference number: GID-TA10203
Discontinued Reference number: GID-TA10767
Discontinued Reference number: GID-TA10859
Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy [ID1172]
Discontinued Reference number: GID-TA10394
Canakinumab and tocilizumab for treating systemic juvenile idiopathic arthritis [ID983]
Discontinued Reference number: GID-TA11241
Lymphoma (diffuse large B-cell, untreated) – liposomal vincristine [ID1123]
Discontinued Reference number: GID-TA11208
Discontinued Reference number: GID-TA10933
Discontinued Reference number: GID-TA10783
In development Reference number: GID-TA11631 Expected publication date: TBC
Discontinued Reference number: GID-HST10020
Discontinued Reference number: GID-TA10166
Baricitinib for treating active autoantibody-positive systemic lupus erythematosus [ID3997]
Discontinued Reference number: GID-TA10892
Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]
Discontinued Reference number: GID-TA10637
Discontinued Reference number: GID-TA10437
Pembrolizumab with epacadostat for untreated malignant melanoma [ID1423]
Discontinued Reference number: GID-TA10330